Ocugen Signs Letter of Intent to Acquire Vaccine Manufacturing, R&D Hub in Ontario, Canada

 

• Dormant Vaccine Manufacturing site currently owned by an affiliate of Liminal BioSciences intended to bring new capabilities to Ocugen’s medicine portfolio of Canadian and U.S. companies

• COVAXIN™ (BBV152), if approved, to be the first product manufactured in new upgraded facility

• New facility includes potential for manufacturing for breakthrough gene therapies and serve as R&D hub

• Site development, refurbishment and manufacturing intended to bring significant new regional economic opportunities

https://finance.yahoo.com/news/ocugen-inc-signs-letter-intent-142500087.html